Develops and commercializes biopharmaceutical products for neurology and immunology diseases. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Every year shown ended in profit.
The market pays 25.9× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 29% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 20% — still a thick cushion, though costs have been eating into it lately.
There is $2.9B in the vault; even if every debt were paid off, $261.0M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.